
COSMIC-312 | XL184-312
NCT03755791
JCP062
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy (COSMIC-312)
Status:
Closed to Accrual

III
Phase

1st
Line of Therapy

Advanced / Metastatic
Disease Stage

Biomarker(s)
N/A
Investigational
Product
Cabozantinib
Tyrosine kinase inhibitor (p.o.)
Treatment Arms
o Experimental: Experimental arm - cabozantinib + atezolizumab
o Active Comparator: Control arm - sorafenib
o Single-Agent Cabozantinib arm